Keros Therapeutics Inc expected to post a loss of $1.35 a share - Earnings Preview

Keros Therapeutics

30/04/2024 13:22

* Keros Therapeutics Inc  KROS.OQ   KROS.O  is expected
to show no
change in quarterly revenue when it reports  results on May 2
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Keros Therapeutics Inc
is for
a loss of $1.35 per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 10 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.5%
in the last three months. ​
    * Wall Street's median 12-month price target for Keros
Therapeutics Inc is $85.50​, above​ its last closing price
of $58.62. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -1.34       -1.37      -1.34     Beat    2.5
 Sep. 30 2023  -1.34       -1.35      -1.33     Beat    1.3
 Jun. 30 2023  -1.33       -1.34      -1.27     Beat    5.1​
 Mar. 31 2023  -1.13       -1.12      -1.26     Missed  -12.2
 ​​Dec.        -1.08       -1.10      -1.09     Beat    0.7
 31 2022                                                
 Sep. 30 2022  -1.23       -1.23      -0.92     Beat    25.3​
 Jun. 30 2022  -1.05       -1.06      -1.13     Missed  -6.8
 Mar. 31 2022  -0.86       -0.86      -1.01     Missed  -17.1
 This summary was machine generated April 30 at 12:22 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)